GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial Amid Global Supply Concerns
GeoVax Labs is preparing to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine in the second half of 2026, addressing critical global supply constraints for orthopoxvirus vaccines while reporting a reduced net loss of $21.5 million for 2025.
GeoVax Labs, Inc. announced its 2025 financial results and operational progress, highlighting preparations for a pivotal Phase 3 trial of its GEO-MVA vaccine targeting mpox and smallpox. The company plans to initiate the Phase 3 immuno-bridging study in the second half of 2026, representing a critical step toward regulatory approval and addressing documented global supply constraints in orthopoxvirus vaccines.
David Dodd, Chairman and CEO of GeoVax, stated that GEO-MVA represents a critically important opportunity to eliminate current global supply constraints while supporting broader public health preparedness and biosecurity objectives. The company received formal Scientific Advice from the European Medicines Agency supporting a streamlined development pathway, including a single Phase 3 study without prior Phase 1 or Phase 2 trials. This regulatory alignment accelerates the potential path to market for a vaccine needed amid recurring global mpox outbreaks and depleted government stockpiles.
The importance of GEO-MVA extends beyond immediate public health needs to strategic biosecurity considerations. The vaccine is positioned at the intersection of evolving viral strains, policy-driven demand for diversified supply, and the need for domestic manufacturing capacity beyond a single foreign source. GeoVax has completed cGMP manufacturing and fill-finish of clinical-grade GEO-MVA, establishing readiness for both clinical supply and potential commercialization. The company is actively aligning the vaccine with public health preparedness frameworks through engagement with international regulatory and governmental stakeholders.
Beyond its priority GEO-MVA program, GeoVax continues to advance other clinical programs. The GEO-CM04S1 COVID-19 vaccine is progressing through multiple Phase 2 trials targeting immunocompromised populations, with data readouts expected in 2026. Interim findings from a chronic lymphocytic leukemia study indicated superior immune responses compared to mRNA comparators. In oncology, the company's Gedeptin® program completed Phase 1/2 evaluation in advanced head and neck cancer and entered an exclusive license agreement with Emory University to support combination use with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $21.5 million for 2025, compared to $25.0 million in 2024. Revenue decreased to $2.5 million from government contracts, primarily associated with the BARDA/RRPV Project NextGen award that was terminated in April 2025. Research and development expenses declined to $18.1 million from $23.7 million, reflecting discontinued costs from the terminated contract and reduced expenses for GEO-CM04S1 and Gedeptin programs. The company ended 2025 with $3.1 million in cash, down from $5.5 million at the end of 2024. Further financial details are available in the company's Securities and Exchange Commission filings.
The advancement of GEO-MVA comes at a critical time for global health security. With orthopoxvirus threats persisting and supply limitations creating vulnerabilities in pandemic preparedness, GeoVax's progress represents a potential solution to a documented gap in medical countermeasures. The company's strategic focus on executing key clinical and regulatory milestones while strengthening partnerships positions it to address both immediate public health needs and long-term biosecurity objectives.